SCHEMBL19953920

SCHEMBL19953920

Cc1nc2cc(N)ccc2c(=O)n1[C@]1(C(=O)OCc2ccccc2)CCC(=O)NC1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 2/20 0.47
▸ CRBN Q96SW2 2/20 0.47
▸ ALDH1A1 P00352 4/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ HPGD P15428 2/20 0.35
▸ LMNA P02545 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ TP53 P04637 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ APP P05067 2/20 0.33
▸ HDAC1 Q13547 2/20 0.33
▸ HDAC2 Q92769 2/20 0.33
▸ HDAC11 Q96DB2 2/20 0.33
▸ HDAC8 Q9BY41 2/20 0.33
▸ HDAC6 Q9UBN7 2/20 0.33
▸ TNF P01375 1/20 0.33
▸ DHFR P00374 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19954318 1.00 DDB1 (0.47) DDB1CRBNALDH1A1KDM4EHPGD
SCHEMBL19953919 1.00 DDB1 (0.47) DDB1CRBNALDH1A1KDM4EHPGD
SCHEMBL23979589 0.95 DDB1 (0.43) DDB1CRBNALDH1A1KDM4EHPGD
SCHEMBL19953924 0.94 CRBN (0.48) DDB1CRBNALDH1A1KDM4EHPGD
SCHEMBL19953921 0.94 CRBN (0.48) DDB1CRBNALDH1A1KDM4EHPGD
SCHEMBL19954310 0.94 CRBN (0.48) DDB1CRBNALDH1A1KDM4EHPGD
SCHEMBL19953918 0.91 CRBN (0.46) DDB1CRBNALDH1A1KDM4ELMNA
SCHEMBL19953932 0.90 CRBN (0.50) DDB1CRBNALDH1A1KDM4ELMNA
SCHEMBL19953928 0.90 CRBN (0.50) DDB1CRBNALDH1A1KDM4ELMNA
SCHEMBL19954299 0.90 CRBN (0.50) DDB1CRBNALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230277539-A1 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME DEUTERX LLC (US) 2023-09-07 — — US disclosed
US-9913845-B2 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same DEUTERX, LLC (US) 2018-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230277539-A1 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME AQP3, AQP4, AQP1 DDB1 3771/4885CRBN 2849/4885ALDH1A1 1102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback